Morten Grunnet

Morten Grunnet serves as an Adjunct Professor in the Department of Drug Design and Pharmacology within the Faculty of Health and Medical Sciences at the University of Copenhagen. His primary professional affiliation appears to be with Lundbeck pharmaceutical company, where he maintains his professional email address (MGRU@lundbeck.com), while contributing academic expertise through his university affiliation. His research focuses on cardiac physiology with particular emphasis on ion channels that regulate electrical activity in the heart.

Dr. Grunnet's primary research interests center on cardiac ion channels, particularly potassium channels including KCa2 (SK channels) and KV11.1, and their role in cardiac electrophysiology and arrhythmias. His work investigates how modulation of these channels affects cardiac function, with specific applications in atrial fibrillation treatment and safety pharmacology. He employs sophisticated animal models, primarily porcine and rabbit systems, to study cardiac electrophysiology under various pathological conditions including myocardial infarction and induced arrhythmias.

Analysis of his recent publications (2019-2025) reveals a consistent research trajectory focused on developing and testing novel antiarrhythmic therapies targeting specific potassium channels. His work demonstrates particular expertise in translational research, moving from basic ion channel physiology to clinical applications, with multiple publications describing phase 1 and phase 2 clinical trials of novel compounds like AP30663. His research frequently examines the balance between therapeutic efficacy and potential pro-arrhythmic risks of channel-modulating drugs.

Dr. Grunnet maintains an active research profile with 113 documented research outputs. His work shows significant collaborative activity, particularly with researchers including Bentzen B.H., Diness J.G., and Holst A.G. His publications appear in high-impact journals including Nature Medicine, British Journal of Clinical Pharmacology, and Frontiers in Pharmacology, indicating recognition of his contributions to the field of cardiac pharmacology and electrophysiology.